Reduced lymphocyte response to PHA and OKT3 in drug-free and neuroleptic-treated chronic schizophrenics.
Monteleone
P
P
Department of Psychiatry, First Medical School, University of Naples, Italy.
Valente
B
B
Maj
M
M
Kemali
D
D
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003692:Delayed-Action Preparations; D004565:Electroconvulsive Therapy; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects* / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000276:immunology*; D010835:Phytohemagglutinins / Q000276:immunology*; D012559:Schizophrenia / Q000188:drug therapy* / Q000276:immunology*; D012565:Schizophrenic Psychology; D013881:Thioridazine / Q000008:administration & dosage / Q000009:adverse effects
D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D016853:Muromonab-CD3; D010835:Phytohemagglutinins; D006220:Haloperidol; D013881:Thioridazine